The trial is enrolling adult women with recurrent ovarian cancer after at least two previous therapies. Credit: Jo Panuwat D / Shutterstock.com. (Jo Panuwat D / Shutterstock.com.) Anixa Biosciences ...
Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...
Drs Ursula A. Matulonis and Marisa R. Nucci discuss the future of AI and pathology and how genetics and genomics play a role ...
Ovarian cancer accounts for more deaths than any other gynecologic cancer. In 2025, the World Health Organization estimates the disease ...
At MSK, close to half of the surgeries just for colorectal cancer are done robotically, Dr. Garcia-Aguilar says. A leader in ...
Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, ...
Evert says her ovarian cancer has returned for a third time, forcing the tennis legend to step away from Wimbledon and other ...
MedPage Today on MSN
Gentler regimen for HER2+ breast cancer gets good grades in 5-year report
After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...
For patients with advanced ovarian cancer, first-line maintenance therapy with rucaparib delays the need for first and second subsequent therapies by roughly a year at each step, according to new data ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This first-in-human, single ...
A novel radiopharmaceutical therapy approach that targets fibroblast activation protein (FAP)—which is highly expressed in many types of cancer—is safe and effective for patients, according to a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results